You are viewing the site in preview mode

Skip to main content

Table 2 In vivo NKG2D ligand expression in sequential Ewing sarcoma tumour samples

From: Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

UPNa sample type (years after diagnosis) MICA ULBP1
1 post-chemotherapy resection-GRb n.e. +
  lung metastasis (2) ++ +
  mediastinal metastasis (3) ++ +
2 pre-treatment biopsy ++ +
  post-chemotherapy resection-GR + ++
  lung metastasis (5) + +/-
  lymph node metastasis (9) ++ n.e.
3 pre-treatment biopsy + +
  post-chemotherapy resection-GR ++ +
  lung metastasis (3) + ++
  lung metastasis (4) + n.e.
4 pre-treatment biopsy + +
  post-chemotherapy resection-PRc ++ +
  bone metastasis (1) ++ -
5 pre-treatment biopsy ++ +/-
  post-chemotherapy resection-PR ++ +
  lung metastasis (1) ++ +/-
6 pre-treatment biopsy ++ -
  post-chemotherapy resection-PR ++ +/-
  lung metastasis (0.5) ++ -
  lung metastasis (2.5) ++ +/-
  lung metastasis (3) ++ +/-
  bone metastasis (3) ++ -
7 post-chemotherapy resection-PR ++ +/-
  lung metastasis (1.5) ++ +
  bone metastasis (2.5) ++ +/-
  lung metastasis (4) ++ +
  lung metastasis (4) ++ +/-
  lung metastasis (5) ++ ++
  paravertebral metastasis (5) ++ +
8 pre-treatment biopsy ++ +
  post-chemotherapy resection-GR + n.e.
  lung metastasis (8) ++ +
  1. aUPN = unique patient number. bGR = good chemotherapy response. cPR = poor chemotherapy
  2. response. n.e. = not evaluable.-= absent, +/- = weak, + = moderate, ++ = strong expression.
Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329